Compare Stocks: IRON, KURA, JANX, and ABUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.01 -1.2%	$4.79	$3.50 ▼ $5.45	$1.00B	0.62	5.27 million shs	6.46 million shs
IRON Disc Medicine	$69.53 +0.5%	$76.82	$40.00 ▼ $99.50	$2.66B	0.97	492,754 shs	1.06 million shs
JANX Janux Therapeutics	$16.59 -1.6%	$16.99	$12.12 ▼ $35.34	$1.03B	2.53	882,581 shs	2.45 million shs
KURA Kura Oncology	$11.73 +0.1%	$11.21	$7.36 ▼ $13.90	$1.04B	0.44	1.99 million shs	2.66 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.18%	-2.15%	+0.60%	+10.11%	+13.09%
IRON Disc Medicine	+0.51%	-0.76%	-13.43%	-1.78%	+13.93%
JANX Janux Therapeutics	-1.60%	-2.98%	-5.31%	+16.67%	-29.28%
KURA Kura Oncology	+0.09%	+2.99%	-6.38%	+18.13%	+44.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$5.01 -1.2%	$4.79	$3.50 ▼ $5.45	$1.00B	0.62	5.27 million shs	6.46 million shs
IRON Disc Medicine	$69.53 +0.5%	$76.82	$40.00 ▼ $99.50	$2.66B	0.97	492,754 shs	1.06 million shs
JANX Janux Therapeutics	$16.59 -1.6%	$16.99	$12.12 ▼ $35.34	$1.03B	2.53	882,581 shs	2.45 million shs
KURA Kura Oncology	$11.73 +0.1%	$11.21	$7.36 ▼ $13.90	$1.04B	0.44	1.99 million shs	2.66 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.18%	-2.15%	+0.60%	+10.11%	+13.09%
IRON Disc Medicine	+0.51%	-0.76%	-13.43%	-1.78%	+13.93%
JANX Janux Therapeutics	-1.60%	-2.98%	-5.31%	+16.67%	-29.28%
KURA Kura Oncology	+0.09%	+2.99%	-6.38%	+18.13%	+44.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	-0.20% Downside
IRON Disc Medicine	2.77	Moderate Buy	$110.18	58.47% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	119.78% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	116.54% Upside

Current Analyst Ratings Breakdown

Latest IRON, KURA, JANX, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	IRON Disc Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$79.00 ➝ $86.00
9/10/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/10/2026	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/10/2026	IRON Disc Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$128.00
9/10/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
9/2/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$88.00 ➝ $100.00
9/1/2026	IRON Disc Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/26/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	70.49	N/A	N/A	$0.40 per share	12.53
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
JANX Janux Therapeutics	$10M	101.43	N/A	N/A	$15.91 per share	1.04
KURA Kura Oncology	$67.48M	15.46	N/A	N/A	$2.00 per share	5.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	6.34	N/A	N/A	84.22%	90.98%	82.34%	11/16/2026 (Estimated)
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	11/5/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)

Latest IRON, KURA, JANX, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
IRON Disc Medicine	0.09	24.14	24.14
JANX Janux Therapeutics	N/A	16.35	16.35
KURA Kura Oncology	0.12	4.73	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
IRON Disc Medicine	83.70%
JANX Janux Therapeutics	75.39%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
IRON Disc Medicine	3.76%
JANX Janux Therapeutics	7.90%
KURA Kura Oncology	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	19	198.11 million	158.68 million	Optionable
IRON Disc Medicine	165	38.39 million	3.69 million	Not Optionable
JANX Janux Therapeutics	113	61.14 million	56.31 million	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable

IRON, KURA, JANX, and ABUS Headlines

Recent News About These Companies

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16 at 2:00 PM | seekingalpha.com

Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of "Moderate Buy" from Analysts

September 16 at 2:28 AM | americanbankingnews.com

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

September 16 at 2:28 AM | marketbeat.com

Kura spins diabetes work into a Lilly-backed biotech startup

September 9, 2026 | finance.yahoo.com

Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes

September 9, 2026 | pharmexec.comP

Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

September 9, 2026 | fiercebiotech.comF

Kura Oncology Names Jennifer Fulk CFO

September 9, 2026 | rttnews.com

Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea

September 9, 2026 | statnews.comS

Kura Oncology launches diabetes-focused Caspian Therapeutics

September 9, 2026 | cen.acs.orgC

Kura Oncology Launches Caspian Therapeutics With $50 Million Funding

September 9, 2026 | finance.yahoo.com

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

September 9, 2026 | globenewswire.com

Kura Oncology Names Jennifer Fulk Chief Financial Officer

September 8, 2026 | marketwatch.com

Kura Oncology, Inc. : changements au sein de la direction, effectifs au 8 septembre 2026

September 8, 2026 | zonebourse.comZ

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

September 8, 2026 | globenewswire.com

Bank of New York Mellon Corp Makes New $2.83 Million Investment in Kura Oncology, Inc. $KURA

September 7, 2026 | marketbeat.com

Corient Private Wealth LP Takes Position in Kura Oncology, Inc. $KURA

September 5, 2026 | marketbeat.com

Kura Oncology (KURA) Receives a Buy from Mizuho Securities

September 4, 2026 | theglobeandmail.com

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Pale Fire Capital SE Sells 800,874 Shares of Kura Oncology, Inc. $KURA

September 3, 2026 | marketbeat.com

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

September 1, 2026 | zacks.com

Kura Oncology to Participate in Three Investor Conferences in September

September 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRON, KURA, JANX, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$5.01 -0.06 (-1.18%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.99 -0.02 (-0.32%)

As of 09/18/2026 07:38 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Disc Medicine NASDAQ:IRON

$69.53 +0.35 (+0.51%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$69.40 -0.13 (-0.18%)

As of 09/18/2026 07:38 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Janux Therapeutics NASDAQ:JANX

$16.59 -0.27 (-1.60%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.59 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Kura Oncology NASDAQ:KURA

$11.73 +0.01 (+0.09%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.80 +0.07 (+0.61%)

As of 09/18/2026 08:00 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRON, KURA, JANX, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRON, KURA, JANX, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRON, KURA, JANX, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRON, KURA, JANX, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Disc Medicine NASDAQ:IRON

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRON, KURA, JANX, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRON, KURA, JANX, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRON, KURA, JANX, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRON, KURA, JANX, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Disc Medicine NASDAQ:IRON

Janux Therapeutics NASDAQ:JANX

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools